VOR - Latest News
Vor Biopharma Inc. (VOR), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $1.25B. Trailing twelve-month P/E ratio is 1.99. Beta to the broader market is 1.72.
The article list below shows the most recent VOR headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent VOR Headlines
Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com - Aug 11, 2026
Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 E
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - Aug 3, 2026
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune dise
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - Aug 3, 2026
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune dise
Vor Bio Appoints David Zaccardelli to Board of Directors
globenewswire.com - Jul 7, 2026
BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune disea
Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes
seekingalpha.com - Jul 7, 2026
Vor Biopharma (VOR) has transformed into a late-stage autoimmune drug developer, focusing on telitacicept, a dual BAFF/APRIL inhibitor with multiple C
How News Affects VOR Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track VOR's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked VOR news questions
- What is the latest VOR news headline?
- The most recent VOR headline (Aug 11, 2026) is "Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the VOR news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What VOR news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual VOR options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.